We take great pride in our ability to provide innovative solutions. Over the past few years, we have launched 25 innovative products (including extensions) that were launched for the first time in India. Our pipeline is strong and we are poised to launch 50 more innovative products over the next couple of years.

Main Products:
Products Innovation
Chymonac tablets(First to launch in India) To manage post-surgical inflammatory pain, Indian market has brands which are either NSAID alone, combination of NSAID and paracetamol or proteolytic enzyme products (like serratiopeptidase, trypsin-chymotrypsin). As the individual mode of action of each is different and to manage post-operative inflammatory pain in the most effective manner, a combination of gastro-protective NSAID - aceclofenac, paracetamol and trypsin – chymotrypsin was introduced by Wanbury which was a unique first-time entrant in the market.
Glopink capsule(First to launch in India) Wanbury is the first to launch the concept of benefit of multiple micronutrients in pregnancy. This is a unique formula containing 27 essential micro-nutrients along with 100 mg DHA.
P Mute(First to launch in India) Wanbury was first to launch Nabumetone in 1000 mg strength – which is actually the recommended dose. Other brands in the market had low strength.
Osteocerin(First to launch in India) Wanbury was first in the market to launch this novel composition. Other brands in the market only had either Diacerein or Glucosamine
Traceta Tablet(Early mover) Wanbury was amongst the earliest movers in the market for this formulation.
Thrombostat (First to launch in India) Wanbury was the first to launch this strength of Enoxaparin (30 mg per 0.3 ml) in the Indian market.
Etosafe ER Tablet(First to launch in India) Wanbury was the first to launch Etodolac in extended release form in the right strength (600 mg).
Menaq Tablet(Early mover) Wanbury was one of the early movers in the Indian market to launch this product.
Nitrofur SR tablet (First to launch in India) Wanbury was first to launch this unique formulation of Nitrofurantoin in Indian market
LorQRS Tablet(First to launch in India) Wanbury was first to launch Lornoxicam in quick release formulation in the Indian market.
LorQRS - 4 Tablet(First to launch in India) Wanbury was first to launch Lornoxicam in quick release formulation in the Indian market.
Wellbone Infusion(Early mover) Wanbury was an early mover in this formulation in the Indian market.
LorQRS - P Tablet(First to launch in India) Wanbury was first to launch combination of Lornoxicam in quick release formulation along with Paracetamol in the Indian market.
Lortrio Tablet(First to launch in India) To manage post-surgical inflammatory pain in orthopedics, Indian market has brands which are either NSAID alone, combination of NSAID and paracetamol or proteolytic enzyme products (like serratiopeptidase, trypsin-chymotrypsin). As the individual mode of action of each is different and to manage post-operative inflammatory pain in the most effective manner, a combination of lornoxicam, paracetamol and trypsin – chymotrypsin was introduced by Wanbury which was a unique first-time entrant in the market.
Singlor Tablet(First to launch in India) Wanbury was first to launch Lornoxicam in a combination of immediate and sustained release in the Indian market.
LorQRS- T Tablet(First to launch in India) Wanbury was first to launch Lornoxicam in quick release formulation in combination with Thiocolchicoside in the Indian market.
Bonefit Capsules(First to launch in India) Wanbury was first to launch this unique combination with ingredients like Green tea extract, Lutein, Zeaxanthin in the Indian market.
D- Infla Gel(Different combination compared to competition) Wanbury has recently launched this unique diclofenac micro-emulsion gel with penetration enhancers, which is different than other diclofenac topical preparations in the market.
Unito tablet(First to launch in India) Wanbury was first to launch this combination in the Indian market.
RabiPlus fast (Early mover) Wanbury was one of the early movers in this market.